CR Boya Bio-pharmaceutical reports mixed Q3 financials: revenue up, profit down

China Resources Pharmaceutical Group Limited announced the unaudited financial results for its subsidiary, CR Boya Bio-pharmaceutical, for the nine months ended September 30, 2025. The company reported revenue of 1,473,924,123.26 yuan, an increase from 1,245,107,779.60 yuan in the same period of 2024. However, net profit saw a decrease, falling to 343,042,957.61 yuan from 412,432,277.86 yuan reported in 2024.

The company's cash and cash equivalents experienced a significant net decrease of 536,817,463.21 yuan, contrasting with a net increase of 38,641,814.80 yuan in the prior year. Consequently, cash and cash equivalents at the end of the period stood at 761,753,926.76 yuan, down from 1,988,439,866.94 yuan in 2024. Total assets reached 8,727,110,907.17 yuan, while total liabilities were 1,054,662,143.39 yuan as of September 30, 2025.

China Resources Pharmaceutical Group indirectly holds approximately 30.48% of the total share capital and 41.79% voting rights in CR Boya Bio-pharmaceutical. The announced financials are unaudited and prepared according to PRC Generally Accepted Accounting Principles. Shareholders and potential investors are advised to exercise caution as these figures may be subject to adjustment during a formal audit.